Communiqués Hyloris Pharmaceuticals SA

Actions

HYL

BE0974363955

Produits pharmaceutiques

PEA

PEA/PME

Temps réel Euronext Bruxelles Autres places de cotation 17:18:04 09/06/2026			Varia. 5j.	Varia. 1 janv.
4,950 ^EUR	-1,00 %		-3,32 %	-27,63 %

26/03	Hyloris Pharmaceuticals SA publie ses résultats pour l'exercice clos le 31 décembre 2025	CI
20/01	Hyloris Pharmaceuticals s'associe à Orion pour la commercialisation d'un traitement contre l'acidité gastrique	MT

Communiqués

20/05	Hyloris Pharmaceuticals : Non-Regulated information Hyloris welcomed for Exclusive Company Visit ENGLISH VERSION	PU
08/05	Hyloris Pharmaceuticals : Regulated Information Hyloris’ Annual General Shareholders Meeting on June 9, 2026 ENGLISH VERSION	PU
30/04	Hyloris Pharmaceuticals : releases Annual Report 2025	PU
30/04	Hyloris Pharmaceuticals : Regulated Information Hyloris releases Annual Report 2025 FRENCH VERSION	PU
30/04	Hyloris Pharmaceuticals : Regulated Information Hyloris releases Annual Report 2025 ENGLISH VERSION	PU
31/03	Hyloris Pharmaceuticals : Regulated Information Information on the Total Number of Voting Rights and Shares (Denominator) FRENCH VERSION	PU
26/03	Consolidated Results 2025 - Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones	PU
26/03	Inside Information Consolidated Results 2025 - Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones FRENCH VERSION	PU
19/02	Hyloris Pharmaceuticals : Inside Information Hyloris Provides Update on FDA Review of Valacyclovir for Oral Suspension ENGLISH VERSION	PU
19/02	Hyloris Pharmaceuticals : Inside Information Hyloris Provides Update on FDA Review of Valacyclovir for Oral Suspension FRENCH VERSION	PU
19/02	Hyloris Pharmaceuticals : Provides Update on FDA Review of Valacyclovir for Oral Suspension	PU
02/02	Hyloris Pharmaceuticals : Disclosure of a received transparency notification in accordance with article 14 of the act of 2 May 2007 on disclosure of large shareholdings	PU
02/02	Hyloris Pharmaceuticals : Regulated Information Information on the Total Number of Voting Rights and Shares (Denominator) FRENCH VERSION	PU
19/01	Hyloris Pharmaceuticals : Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets	PU
19/01	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets ENGLISH VERSION	PU
19/01	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets FRENCH VERSION	PU
30/12	Hyloris Pharmaceuticals : Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMed	PU
30/12	Hyloris Pharmaceuticals : Inside Information Hyloris Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMed ENGLISH VERSION	PU
29/12	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. ENGLISH VERSION	PU
29/12	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. FRENCH VERSION	PU
11/12	Hyloris Pharmaceuticals : Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder	PU
11/12	Hyloris Pharmaceuticals : Non-Regulated Information Hyloris Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder ENGLISH VERSION	PU
11/12	Hyloris Pharmaceuticals : Non-Regulated Information Hyloris Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder FRENCH VERSION	PU
19/11	Hyloris Pharmaceuticals : Board of Directors appoints Stijn Van Rompay as CEO	PU
19/11	Hyloris Pharmaceuticals : Inside Information Hyloris Board of Directors appoints Stijn Van Rompay as CEO ENGLISH VERSION	PU